Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) fell 6.5% on Monday . The stock traded as low as $10.50 and last traded at $10.50. 5,786 shares were traded during mid-day trading, a decline of 90% from the average session volume of 57,892 shares. The stock had previously closed at $11.23.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on MLTX. Jefferies Financial Group began coverage on MoonLake Immunotherapeutics in a report on Friday, November 11th. They issued a "buy" rating and a $16.00 price objective for the company. Lifesci Capital restated an "outperform" rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, December 21st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, MoonLake Immunotherapeutics has a consensus rating of "Buy" and an average price target of $20.33.
Get
MoonLake Immunotherapeutics alerts:
MoonLake Immunotherapeutics Price Performance
The company has a fifty day simple moving average of $10.26 and a two-hundred day simple moving average of $8.52.
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) last posted its earnings results on Monday, November 14th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. Equities research analysts forecast that MoonLake Immunotherapeutics will post -1.4 EPS for the current fiscal year.
Institutional Trading of MoonLake Immunotherapeutics
Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new stake in shares of MoonLake Immunotherapeutics during the second quarter valued at $62,000. Cowen AND Company LLC acquired a new stake in MoonLake Immunotherapeutics in the 2nd quarter worth about $85,000. Meridian Wealth Management LLC acquired a new stake in MoonLake Immunotherapeutics in the 2nd quarter worth about $142,000. Millennium Management LLC acquired a new stake in MoonLake Immunotherapeutics in the 2nd quarter worth about $147,000. Finally, TD Asset Management Inc. acquired a new stake in MoonLake Immunotherapeutics in the 2nd quarter worth about $152,000. Institutional investors and hedge funds own 76.13% of the company's stock.
MoonLake Immunotherapeutics Company Profile
(Get Rating)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
Read More
- Get a free copy of the StockNews.com research report on MoonLake Immunotherapeutics (MLTX)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
